Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Atara Biotherapeutics Inc.

Latest From Merck Lipha

Alinea Pharmaceuticals Inc.

Alinea Pharmaceuticals was founded recently around three in-licensed development programs, encompassing a Phase II-ready molecule to treat diabetic complications, a set of leads against a novel serum glucose-regulating target of significant interest to Big Pharma, and a research program around novel methods for lipid control.
BioPharmaceutical Research and Development Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Infectious & Viral Diseases
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Atara Biotherapeutics Inc.
  • Senior Management
  • Isaac Ciechanover, MD, Pres. & CEO
    John F McGrath, Jr., EVP, CFO
    Christopher Haqq, MD, PhD, EVP, R&D & CMO
    Gad Soffer, EVP, Chief Strategy Officer
  • Contact Info
  • Atara Biotherapeutics Inc.
    Phone: (650) 278-8930
    611 Gateway Blvd.
    Ste. 900
    South San Francisco, CA 94080